mRNAs for Vaccine Development

mRNA vaccines have been authorized for emergency use much less than one year after the emergence of COVID-19, demonstrating the extremely good improvement pace of the mRNA platform technology. However, even as the versatility of the mRNA platform could permit for the global development of latest vaccines, constraints which includes restrained intellectual property (IP), excessive price of goods, raw material bottlenecks, and shortage of skilled workforce restriction access to mRNA vaccines in low- and middle-earnings countries. Here, Seattle Genova presents a perspective on the global state of mRNA vaccine development for infectious diseases, and the manufacturing capabilities needed to enable vaccine access to fight ongoing/future pandemic and epidemic threats.